Published in Trends Pharmacol Sci on February 19, 2010
Informatics and standards for nanomedicine technology. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 1.19
In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles. Proc Natl Acad Sci U S A (2011) 1.10
Green synthesis of silver nanoparticles by Chrysanthemum morifolium Ramat. extract and their application in clinical ultrasound gel. Int J Nanomedicine (2013) 0.99
Probing nanoparticle translocation across the permeable endothelium in experimental atherosclerosis. Proc Natl Acad Sci U S A (2014) 0.98
Silicon micro- and nanofabrication for medicine. Adv Healthc Mater (2013) 0.90
Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis. Theranostics (2014) 0.87
Gold nanoparticles - the theranostic challenge for PPPM: nanocardiology application. EPMA J (2013) 0.85
The nanomedicine revolution: part 2: current and future clinical applications. P T (2012) 0.85
Critical evaluation of biodegradable polymers used in nanodrugs. Int J Nanomedicine (2013) 0.84
Delivering regenerative cues to the heart: cardiac drug delivery by microspheres and peptide nanofibers. J Cardiovasc Transl Res (2010) 0.84
The cargo of CRPPR-conjugated liposomes crosses the intact murine cardiac endothelium. J Control Release (2012) 0.83
The nanomedicine revolution: part 1: emerging concepts. P T (2012) 0.83
The Protein Corona of Plant Virus Nanoparticles Influences their Dispersion Properties, Cellular Interactions, and In Vivo Fates. Small (2016) 0.81
Acoustic cardiac signals analysis: a Kalman filter-based approach. Int J Nanomedicine (2012) 0.81
The prevention and regression of atherosclerotic plaques: emerging treatments. Vasc Health Risk Manag (2012) 0.80
Integration of biosensors and drug delivery technologies for early detection and chronic management of illness. Sensors (Basel) (2013) 0.79
Cytotoxic Activity of Highly Purified Silver Nanoparticles Sol Against Cells of Human Immune System. Appl Biochem Biotechnol (2015) 0.78
Tailoring polymersome bilayer permeability improves enhanced permeability and retention effect for bioimaging. ACS Appl Mater Interfaces (2014) 0.78
Therapeutic Efficacy of an ω-3-Fatty Acid-Containing 17-β Estradiol Nano-Delivery System against Experimental Atherosclerosis. PLoS One (2016) 0.77
Antibacterial activity of neem nanoemulsion and its toxicity assessment on human lymphocytes in vitro. Int J Nanomedicine (2015) 0.75
Accessing to the minor proteome of red blood cells through the influence of the nanoparticle surface properties on the corona composition. Int J Nanomedicine (2015) 0.75
Cardiovascular nanomedicine: a posse ad esse. Methodist Debakey Cardiovasc J (2012) 0.75
Atherosclerosis and Nanotechnology: Diagnostic and Therapeutic Applications. Cardiovasc Drugs Ther (2016) 0.75
Serum albumin 'camouflage' of plant virus based nanoparticles prevents their antibody recognition and enhances pharmacokinetics. Biomaterials (2016) 0.75
Nanomedicine Meets microRNA: Current Advances in RNA-Based Nanotherapies for Atherosclerosis. Arterioscler Thromb Vasc Biol (2016) 0.75
Future of the Renal Biopsy: Time to Change the Conventional Modality Using Nanotechnology. Int J Biomed Imaging (2017) 0.75
Quantum dots for live cells, in vivo imaging, and diagnostics. Science (2005) 21.62
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med (2006) 15.60
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med (2004) 15.30
Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer (2005) 13.49
Nanowire nanosensors for highly sensitive and selective detection of biological and chemical species. Science (2001) 10.93
Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med (2004) 7.12
Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med (2007) 5.77
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37
Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med (2007) 4.95
Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev (2006) 4.69
Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation (2006) 4.35
Nanoshell-enabled photonics-based imaging and therapy of cancer. Technol Cancer Res Treat (2004) 4.06
Evolution of nanoporosity in dealloying. Nature (2001) 3.96
Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation (2007) 3.85
Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med (2007) 3.84
Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation (2003) 3.68
Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation (2003) 3.58
Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation (1996) 3.58
Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med (2007) 3.40
Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A (2007) 2.99
Antibiofouling polymer-coated gold nanoparticles as a contrast agent for in vivo X-ray computed tomography imaging. J Am Chem Soc (2007) 2.78
Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl (2009) 2.74
It's time for a change to a troponin standard. Circulation (2000) 2.69
Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn Reson Med (2005) 2.55
Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol (2006) 2.45
Multiple label-free biodetection and quantitative DNA-binding assays on a nanomechanical cantilever array. Proc Natl Acad Sci U S A (2002) 2.32
A liposomal nanoscale contrast agent for preclinical CT in mice. AJR Am J Roentgenol (2006) 2.21
Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol (1999) 2.15
Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc Imaging (2008) 2.14
Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation (2002) 2.01
Optical and multimodality molecular imaging: insights into atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.84
Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med (2004) 1.83
18F labeled nanoparticles for in vivo PET-CT imaging. Bioconjug Chem (2009) 1.78
Homocysteine and cardiovascular disease: current evidence and future prospects. Am J Med (2002) 1.72
The rational design of nitric oxide selectivity in single-walled carbon nanotube near-infrared fluorescence sensors for biological detection. Nat Chem (2009) 1.64
Magnetic nanoparticles for MR imaging: agents, techniques and cardiovascular applications. Basic Res Cardiol (2008) 1.60
Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano Lett (2007) 1.58
Nanogeometry: beyond drug delivery. Nat Nanotechnol (2008) 1.54
Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Catheter Cardiovasc Interv (2003) 1.54
Use of saliva-based nano-biochip tests for acute myocardial infarction at the point of care: a feasibility study. Clin Chem (2009) 1.51
Molecular photoacoustic tomography with colloidal nanobeacons. Angew Chem Int Ed Engl (2009) 1.47
In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation (2004) 1.45
Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics. Ann Biomed Eng (2009) 1.39
Mitotic trafficking of silicon microparticles. Nanoscale (2009) 1.35
Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets. J Am Chem Soc (2008) 1.31
A highly sensitive and selective diagnostic assay based on virus nanoparticles. Nat Nanotechnol (2009) 1.15
Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles. Nanomedicine (Lond) (2006) 1.13
Visualizing sodium dynamics in isolated cardiomyocytes using fluorescent nanosensors. Proc Natl Acad Sci U S A (2009) 1.09
Detecting vascular biosignatures with a colloidal, radio-opaque polymeric nanoparticle. J Am Chem Soc (2009) 1.08
Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis. Nanomedicine (Lond) (2007) 1.08
Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol Imaging (2008) 1.07
Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Arterioscler Thromb Vasc Biol (2008) 1.07
Sensitive and efficient detection of thrombus with fibrin-specific manganese nanocolloids. Chem Commun (Camb) (2009) 1.03
Sol-gel hydroxyapatite coatings on stainless steel substrates. Biomaterials (2002) 1.00
Nanoporous surfaces as harvesting agents for mass spectrometric analysis of peptides in human plasma. J Proteome Res (2006) 0.98
Cell-based indicator to visualize picomolar dynamics of nitric oxide release from living cells. Anal Chem (2006) 0.96
In vitro characterization of a novel, tissue-targeted ultrasonic contrast system with acoustic microscopy. J Acoust Soc Am (1998) 0.96
Long-residence-time nano-scale liposomal iohexol for X-ray-based blood pool imaging. Acad Radiol (2003) 0.94
Enhanced endothelial cell density on NiTi surfaces with sub-micron to nanometer roughness. Int J Nanomedicine (2008) 0.93
Nanomedicine for the management of lung and blood diseases. Nanomedicine (Lond) (2009) 0.90
Nanoparticulate carriers for the treatment of coronary restenosis. Int J Nanomedicine (2007) 0.90
Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials (2005) 0.88
MR three-dimensional molecular imaging of intramural biomarkers with targeted nanoparticles. J Cardiovasc Magn Reson (2006) 0.87
nan'o.tech.nol'o.gy n. Nat Nanotechnol (2006) 0.87
Mini sensing chip for point-of-care acute myocardial infarction diagnosis utilizing micro-electro-mechanical system and nano-technology. Adv Exp Med Biol (2009) 0.85
Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats. Arterioscler Thromb Vasc Biol (2000) 0.85
Tiny solutions for giant cardiac problems. Trends Cardiovasc Med (2005) 0.84
Polyelectrolyte nanoparticles mediate vascular gene delivery. Pharm Res (2004) 0.84
Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 Trial. Am Heart J (2009) 0.83
A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model. Catheter Cardiovasc Interv (2006) 0.83
The evolving impact of microfabrication and nanotechnology on stent design. J Vasc Surg (2006) 0.81
Drug loading of nanoporous TiO2 films. Biomed Mater (2006) 0.79
HVJ-AVE liposome-mediated Tissue Factor Pathway Inhibitor (TFPI) gene transfer with recombinant TFPI (rTFPI) irrigation attenuates restenosis in atherosclerotic arteries. Int J Cardiol (2008) 0.78
Delivery of nano-objects to functional sub-domains of healthy and failing cardiac myocytes. Nanomedicine (Lond) (2007) 0.78
[Direct gene transfer in the rat kidney in vivo]. Arch Mal Coeur Vaiss (1997) 0.77
A novel point of care diagnostic device: impedimetric detection of a biomarker in whole blood. Conf Proc IEEE Eng Med Biol Soc (2007) 0.77
Efficacy of ion-selective probes in early epicardial in vivo detection of myocardial ischemia. Physiol Meas (2004) 0.76
Physics of magnetic resonance. J Reprod Med (1992) 0.76
Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol (2008) 3.78
Intravascular delivery of particulate systems: does geometry really matter? Pharm Res (2008) 3.13
Clinical proteomics: written in blood. Nature (2003) 2.81
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl (2009) 2.74
Nanotechnologies for biomolecular detection and medical diagnostics. Curr Opin Chem Biol (2006) 2.74
Seven challenges for nanomedicine. Nat Nanotechnol (2008) 2.59
Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol (2010) 2.17
Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol (2012) 1.85
Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials (2007) 1.72
Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J Control Release (2011) 1.72
Tailored porous silicon microparticles: fabrication and properties. Chemphyschem (2010) 1.71
Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows. Nanotechnology (2009) 1.63
The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials (2009) 1.63
What does physics have to do with cancer? Nat Rev Cancer (2011) 1.59
Morphologic instability and cancer invasion. Clin Cancer Res (2005) 1.55
Nanogeometry: beyond drug delivery. Nat Nanotechnol (2008) 1.54
Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res (2009) 1.53
Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One (2010) 1.49
Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. J Math Biol (2008) 1.48
Osmotic pressure beyond concentration restrictions. J Phys Chem B (2007) 1.46
Biotechnology apprenticeship for secondary-level students: teaching advanced cell culture techniques for research. Cell Biol Educ (2002) 1.45
Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res (2011) 1.45
Hesperetin impairs glucose uptake and inhibits proliferation of breast cancer cells. Cell Biochem Funct (2012) 1.44
T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci U S A (2003) 1.37
Antibiological barrier nanovector technology for cancer applications. Expert Opin Drug Deliv (2007) 1.36
Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Adv (2012) 1.35
Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast Cancer Bearing Mice. Adv Funct Mater (2012) 1.35
Mitotic trafficking of silicon microparticles. Nanoscale (2009) 1.35
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
Cellular association and assembly of a multistage delivery system. Small (2010) 1.32
Biodegradable porous silicon barcode nanowires with defined geometry. Adv Funct Mater (2010) 1.31
Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation. J Biomed Mater Res A (2010) 1.31
Mathematical modeling of cancer progression and response to chemotherapy. Expert Rev Anticancer Ther (2006) 1.30
Multiparameter computational modeling of tumor invasion. Cancer Res (2009) 1.28
Enabling individualized therapy through nanotechnology. Pharmacol Res (2010) 1.28
Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci (2011) 1.27
Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest (2014) 1.26
The preferential targeting of the diseased microvasculature by disk-like particles. Biomaterials (2012) 1.25
Interstitial stress and fluid pressure within a growing tumor. Ann Biomed Eng (2003) 1.25
Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta (2010) 1.23
Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res (2013) 1.21
Logic-embedded vectors for intracellular partitioning, endosomal escape, and exocytosis of nanoparticles. Small (2010) 1.19
Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting. PLoS One (2010) 1.19
Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv Healthc Mater (2011) 1.16
Quantitative mechanics of endothelial phagocytosis of silicon microparticles. Cytometry A (2009) 1.16
Tailoring of the nanotexture of mesoporous silica films and their functionalized derivatives for selectively harvesting low molecular weight protein. ACS Nano (2010) 1.16
Design of bio-mimetic particles with enhanced vascular interaction. J Biomech (2009) 1.15
Intracellular trafficking of silicon particles and logic-embedded vectors. Nanoscale (2010) 1.15
Laparoscopic treatment of splenic artery aneurysms. J Vasc Surg (2009) 1.13
E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow. Adv Mater (2011) 1.12
Nanotechnology for breast cancer therapy. Biomed Microdevices (2009) 1.10
Mesoporous silica chips for selective enrichment and stabilization of low molecular weight proteome. Proteomics (2010) 1.08
Adult and umbilical cord blood-derived platelet-rich plasma for mesenchymal stem cell proliferation, chemotaxis, and cryo-preservation. Biomaterials (2012) 1.07
Human lung cancer cells grown in an ex vivo 3D lung model produce matrix metalloproteinases not produced in 2D culture. PLoS One (2012) 1.07
The transport of nanoparticles in blood vessels: the effect of vessel permeability and blood rheology. Ann Biomed Eng (2008) 1.07
Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget (2011) 1.06
Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. Cancer Lett (2012) 1.06
Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small (2013) 1.05
Near-infrared imaging method for the in vivo assessment of the biodistribution of nanoporous silicon particles. Mol Imaging (2011) 1.04
Nanotechnology and tumor imaging: seizing an opportunity. Mol Imaging (2004) 1.04
Engineering multi-stage nanovectors for controlled degradation and tunable release kinetics. Biomaterials (2013) 1.03
Recommendations of the National Heart, Lung, and Blood Institute Nanotechnology Working Group. Circulation (2003) 1.02
Enhanced MRI relaxivity of Gd(3+) -based contrast agents geometrically confined within porous nanoconstructs. Contrast Media Mol Imaging (2012) 1.02
Tailoring width of microfabricated nanochannels to solute size can be used to control diffusion kinetics. J Control Release (2005) 1.02
An integrated approach for the rational design of nanovectors for biomedical imaging and therapy. Adv Genet (2010) 1.00
Modulating cellular adhesion through nanotopography. Biomaterials (2009) 0.99
A robust nanofluidic membrane with tunable zero-order release for implantable dose specific drug delivery. Lab Chip (2010) 0.99
Chlamydophila pneumoniae phospholipase D (CpPLD) drives Th17 inflammation in human atherosclerosis. Proc Natl Acad Sci U S A (2012) 0.99
A low-voltage electrokinetic nanochannel drug delivery system. Lab Chip (2011) 0.99
Adhesion of microfabricated particles on vascular endothelium: a parametric analysis. Ann Biomed Eng (2004) 0.99
Fractionation of serum components using nanoporous substrates. Bioconjug Chem (2006) 0.98
Mesoporous silica as a membrane for ultra-thin implantable direct glucose fuel cells. Lab Chip (2011) 0.98
Nanoporous surfaces as harvesting agents for mass spectrometric analysis of peptides in human plasma. J Proteome Res (2006) 0.98
Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44. Biochemistry (2010) 0.96
The margination propensity of spherical particles for vascular targeting in the microcirculation. J Nanobiotechnology (2008) 0.95
Nanotechnology in medicine: from inception to market domination. J Drug Deliv (2012) 0.95
Short and long term, in vitro and in vivo correlations of cellular and tissue responses to mesoporous silicon nanovectors. Small (2012) 0.95
Abdominal aortic aneurysm: contrast-enhanced US for missed endoleaks after endoluminal repair. Radiology (2004) 0.94
Delivery of gene silencing agents for breast cancer therapy. Breast Cancer Res (2013) 0.94
Vectoring siRNA therapeutics into the clinic. Nat Rev Clin Oncol (2010) 0.94
Nanochannel technology for constant delivery of chemotherapeutics: beyond metronomic administration. Pharm Res (2010) 0.94
Modeling of nanotherapeutics delivery based on tumor perfusion. New J Phys (2013) 0.94
Controlled-release microchips. Expert Opin Drug Deliv (2006) 0.94
Multistage Mesoporous Silicon-based Nanocarriers: Biocompatibility with Immune Cells and Controlled Degradation in Physiological Fluids. Controll Release Newsl (2008) 0.93
In silico vascular modeling for personalized nanoparticle delivery. Nanomedicine (Lond) (2012) 0.93